DIAGNOS Inc. News
-
DIAGNOS celebrates the launch of Labtician’s new screening service for diabetic retinopathy in Ontario and renews its distribution agreement
May 21, 2024 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
DIAGNOS Announces Closing of First Tranche of Private Placement
May 09, 2024 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
DIAGNOS to Present Cutting-Edge AI Solutions for Retinal Health at ARVO 2024
May 06, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a provider…
-
DIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certification
April 16, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a provider…
-
DIAGNOS Inc. to Present at the AI & Technology Hybrid Investor Conference April 11th
April 9, 2024 (Source) — DIAGNOS Inc. (ADK TSX: OTCQB: DGNOF), based in Montreal, Canada, focused on Artificial Intelligence…
-
DIAGNOS Announces Grant of Stock Options
April 03, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
DIAGNOS Welcomes Dr. Philippe Couillard to its Board of Directors
April 2, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
DIAGNOS Announces Closing of Second and Final Tranche of Private Placement
March 22, 2024 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
DIAGNOS Announces Grant of Stock Options
March 4, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
DIAGNOS Welcomes Mr. Michael Braeuel to its Board of Directors
February 29, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
